CTXR - Citius Pharmaceuticals, Inc.

0.8351
-0.114   -13.591%

Share volume: 941,597
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$0.95
-0.11
-0.12%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 4%
Liquidity 43%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.29%
1 Month
4.31%
3 Months
-30.41%
6 Months
-30.98%
1 Year
-47.15%
2 Year
15.99%
Key data
Stock price
$0.84
P/E Ratio 
0.00
DAY RANGE
$0.78 - $0.96
EPS 
-$3.17
52 WEEK RANGE
$0.63 - $2.48
52 WEEK CHANGE
-$47.15
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$915,385
AVERAGE 30 VOLUME 
$636,440
Company detail
CEO: Leonard L. Mazur
Region: US
Website: citiuspharma.com
Employees: 20
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Citius Pharmaceuticals, Inc. engages in the development and commercialization of critical care products. The company is developing five proprietary products, including Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. MinoWrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, and Halo-Lido, a corticosteroid-lidocaine topical formulation.

Recent news